Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E35.74 EPS (ttm)9.00 Insider Own0.10% Shs Outstand236.14M Perf Week4.88%
Market Cap75.96B Forward P/E19.91 EPS next Y16.16 Insider Trans2.16% Shs Float235.91M Perf Month-3.52%
Income2.14B PEG1.71 EPS next Q3.46 Inst Own92.00% Short Float1.32% Perf Quarter-4.38%
Sales8.34B P/S9.10 EPS this Y35.60% Inst Trans-0.28% Short Ratio2.47 Perf Half Y13.62%
Book/sh40.40 P/B7.96 EPS next Y23.33% ROA17.70% Target Price376.76 Perf Year29.07%
Cash/sh6.66 P/C48.29 EPS next 5Y20.90% ROE24.10% 52W Range230.25 - 358.89 Perf YTD15.06%
Dividend- P/FCF32.20 EPS past 5Y24.10% ROI20.70% 52W High-10.37% Beta1.19
Dividend %- Quick Ratio1.70 Sales past 5Y11.10% Gross Margin87.20% 52W Low39.70% ATR12.13
Employees6850 Current Ratio2.00 Sales Q/Q40.50% Oper. Margin35.80% RSI (14)50.70 Volatility4.37% 3.45%
OptionableYes Debt/Eq0.06 EPS Q/Q46.10% Profit Margin25.60% Rel Volume1.00 Prev Close316.06
ShortableYes LT Debt/Eq0.06 EarningsOct 22 BMO Payout0.00% Avg Volume1.25M Price321.67
Recom2.20 SMA201.37% SMA50-2.05% SMA2001.50% Volume1,260,246 Change1.77%
22-Oct-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
19-Aug-14Resumed Stifel Buy $376
29-Jul-14Reiterated Argus Buy $360 → $385
24-Jul-14Reiterated UBS Neutral $330 → $354
09-Jul-14Reiterated RBC Capital Mkts Outperform $325 → $375
19-Mar-14Reiterated Stifel Buy $360 → $376
07-Mar-14Reiterated Barclays Overweight $325 → $352
03-Mar-14Reiterated Stifel Buy $330 → $360
30-Jan-14Reiterated UBS Neutral $300 → $310
30-Jan-14Reiterated Brean Capital Buy $293 → $377
30-Jan-14Reiterated Argus Buy $310 → $360
28-Jan-14Reiterated Deutsche Bank Buy $340 → $415
27-Jan-14Reiterated Canaccord Genuity Buy $291 → $355
16-Jan-14Reiterated Stifel Buy $296 → $321
10-Jan-14Reiterated Barclays Overweight $285 → $325
20-Dec-13Reiterated RBC Capital Mkts Outperform $275 → $325
12-Dec-13Reiterated Argus Buy $280 → $310
30-Oct-13Initiated FBR Capital Mkt Perform $259
29-Oct-13Reiterated Barclays Overweight $240 → $262
17-Jul-13Reiterated Barclays Overweight $220 → $240
24-Oct-14 04:25PM  Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Zacks
23-Oct-14 11:25AM  Citi, Jefferies Weigh In On Biogen Idec Amid Q3 Earnings Benzinga
10:35AM  Fidelity Biotech Fund Cut Biogen Stake Over Five Months at Bloomberg
07:30AM  Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases Business Wire
07:18AM  US STOCKS-Futures inch up, indicating rebound; earnings awaited Reuters
22-Oct-14 06:43PM  Biogen, Thermo Reports Disappoint; Abbott Accelerates at Investor's Business Daily -5.42%
05:18PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:43PM  Markets Reverse Early Morning Gains Following Canadian Shooting Benzinga
04:28PM  As earnings season heats up, stocks close on the lows Yahoo Finance Blogs
04:24PM  Major Indexes End Win Streak; Super Micro Surges at Investor's Business Daily
03:06PM  Stocks Erase Modest Gains; Apple Flirts With Breakout at Investor's Business Daily
01:24PM  Biogen Idec upgraded by Robert W. Baird Briefing.com
12:50PM  Dow Chemical rallies on strong earnings at Financial Times
12:39PM  Why Biogen Idec (BIIB) Stock Is Tanking Today at TheStreet
12:10PM  Biogen's Q3 Earnings Top Estimates, View Raised Again Zacks
09:52AM  Trade-Ideas: Biogen Idec (BIIB) Is Today's Unusual Social Activity Stock at TheStreet
09:05AM  Biogen Takes Breather on Earnings and MS Drug Sales at 24/7 Wall St.
08:30AM  Biogen Idec Inc Earnings Call scheduled for 8:30 am ET today CCBN
08:08AM  Biogen Falls as Top Drugs Sales Fail to Reach Estimates at Bloomberg
07:48AM  [$$] Biogen Idec Sales Surge 37% at The Wall Street Journal
07:24AM  Biogen beats Street 3Q forecasts AP
07:23AM  BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:15AM  Biogen shares rally after beating profit expectations, raising outlook at MarketWatch
07:07AM  Q3 2014 Biogen Idec Inc Earnings Release - Before Market Open CCBN
07:00AM  Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion Business Wire
21-Oct-14 06:48PM  Boeing, AT&T reports due Wednesday; Yahoo up late at MarketWatch
06:47PM  Celgene Rises 8% In Two Days On Crohn's Disease Drug Data Investor's Business Daily
05:03PM  Yahoo, Super Micro Rally After Hours at Investor's Business Daily
11:32AM  Video: Celgene Reports More Good Crohn's Drug Data at Investor's Business Daily
20-Oct-14 03:45PM  Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? Zacks
02:51PM  Will High Price Hurt Gilead Sciences' New Hep-C Drug? at Barrons.com
11:50AM  Will Sangamo (SGMO) Incur Wider-than-Expected Q3 Loss? Zacks
11:16AM  Celgene's Crohn's Disease Drug Hits Its Marks at Investor's Business Daily
18-Oct-14 08:02AM  Celgene, Alexion Among 4 IBD 50 Medicals To Report at Investor's Business Daily
17-Oct-14 11:14AM  3 Stocks Reiterated As A Buy: VZ, WMT, BIIB at TheStreet
16-Oct-14 03:13PM  The Best-Selling Biologic Drugs at Forbes
03:07PM  Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals at Investor's Business Daily
15-Oct-14 05:51PM  US STOCKS-Major indexes end down, but well off session lows Reuters
04:06PM  IPO Stock Watch: Biotech Forward Pharma Falls On IPO at Investor's Business Daily
03:19PM  US STOCKS-Major indexes down more than 1 pct but off day's lows Reuters
12:15PM  US STOCKS-Wall St drops on global economy worry; S&P, Nasdaq down for yr Reuters
08:00AM  Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals Business Wire
13-Oct-14 04:50PM  Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx Zacks
04:33PM  IPO Calendar: Biotech Companies Lead List Of 7 IPOs at Investor's Business Daily
10:05AM  Which Fund Has The Most To Gain From Biogen Idec? Benzinga
08:40AM  UBS Very Positive on Top Biotech Stocks Ahead of Earnings at 24/7 Wall St.
11-Oct-14 08:16AM  Germany's Probiodrug prices Amsterdam listing at up to 32 mln euros Reuters
10-Oct-14 12:14PM  Market bright spots CNBC
10:10AM  Short Interest in Biotech Becomes Company Specific at 24/7 Wall St.
05:37AM  -Isis launches pivotal trial of drug for rare spine disorder Reuters
09-Oct-14 07:26AM  Biogen Idec Inc's Stock Is Set To Drop Benzinga
08-Oct-14 04:01PM  CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 Business Wire
07-Oct-14 07:29PM  Large-Cap Growth Under Repair at Investor's Business Daily
07:01PM  UK cost agency rejects British company GW's cannabis drug Reuters
06-Oct-14 12:38PM  Will Biotech Beat This Earnings Season? at Barrons.com
03-Oct-14 10:30AM  Insider Trading Alert - BIIB, RKUS And PF Traded By Insiders at TheStreet
01-Oct-14 05:00PM  Why October could be bad for biotech Talking Numbers
30-Sep-14 03:17PM  Biogen Idec Inc Still Showing Relative Weakness Compared To Biotech Peers Benzinga
29-Sep-14 06:32PM  Large-Cap Tech Names Hang Tough In Shaky Market at Investor's Business Daily
06:32PM  Biotech Stocks Rebound On Strong Earnings, New Drugs at Investor's Business Daily
26-Sep-14 06:07PM  Multiple Sclerosis Drugs Could Transform Market Again at Investor's Business Daily
25-Sep-14 06:55PM  Technology Stocks Slide But Other Sectors Hold Up Better at Investor's Business Daily
05:34PM  Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 Business Wire
05:17PM  Biotech selloff: What to buy CNBC
05:17PM  [video] Biotech selloff: What to buy at CNBC
04:23PM  Stocks Get Hit Hard; GoPro, Skechers Buck Weakness at Investor's Business Daily
01:31PM  Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains at Investor's Business Daily
12:48PM  Tech trouble sparks wave of selling on Wall Street at CNNMoney.com
11:34AM  Apple Fuels Tech Sell-Off; Valeant Bucks The Trend at Investor's Business Daily
10:50AM  Short Sellers Make Moves in Key Biotech Stocks at 24/7 Wall St.
24-Sep-14 06:15PM  [video] Cramer's favorite large cap biotech plays at CNBC
04:20PM  US STOCKS-Wall St rallies, S&P back above 14-day moving average Reuters
04:16PM  Stocks End Skid; Vertex, Alexion Lead Biotech Rebound at Investor's Business Daily
01:27PM  Acorda To Buy Civitas, Gains Parkinson's Disease Drug at Investor's Business Daily
01:20PM  Stocks Hold Solid Gains; CyberArk Soars In Debut at Investor's Business Daily
23-Sep-14 12:50PM  Biogen Idec: Gene Therapy Push 'Sorely Needed' at Barrons.com
08:00AM  Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index Business Wire
07:00AM  Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy Business Wire
22-Sep-14 07:05PM  Most Big Cap 20 Stocks Near Entries, But Risks Exist at Investor's Business Daily
04:20PM  Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer Zacks
19-Sep-14 01:50PM  Is Merck KGaA on Track with its "Fit for 2018" Program? Zacks
06:43AM  Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Zacks
18-Sep-14 04:10PM  Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 Zacks
10:52AM  2 Columbia Growth Funds Notch Impressive Three-Month Performance Benzinga
07:06AM  Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% Zacks
17-Sep-14 06:15PM  Merck Posts Positive Data on Osteoporosis Drug Odanacatib Zacks
16-Sep-14 07:41AM  Zacks Rank #1 Additions for Tuesday Zacks
15-Sep-14 04:50PM  Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Zacks
02:55PM  Nasdaq Falls Hard, But Apple Resilient On iPhone Orders at Investor's Business Daily
01:04PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
13-Sep-14 08:02AM  Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers at Investor's Business Daily
12-Sep-14 04:30PM  Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Zacks
03:30PM  Biogen Reports Positive Two-Year Data on MS Drug Plegridy Zacks
07:30AM  Detailed Results from Biogen Idec and AbbVies Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) Business Wire
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
02:46PM  Stocks Show Modest Losses; Biotechs Pressured Again at Investor's Business Daily
09:20AM  Short Sellers Remain Vigilant Against Biotechs at 24/7 Wall St.
08:17AM  Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses Benzinga
07:30AM  PLEGRIDY (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients Business Wire
07:30AM  New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients Business Wire
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 03 05:29 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15909,730Feb 03 05:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,586010,097Feb 03 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,159010,044Feb 03 05:15 PM
Rowinsky Eric KDirectorJan 21Sale310.092,020626,38210,440Jan 22 04:49 PM
YOUNG WILLIAMDirectorJan 08Sale285.1115,0004,276,59018,509Jan 09 04:24 PM
PANGIA ROBERT WDirectorJan 06Option Exercise47.556,250297,18820,253Jan 07 12:22 PM
PANGIA ROBERT WDirectorJan 06Sale278.036,2501,737,68814,003Jan 07 12:22 PM
SHERWIN STEPHEN ADirectorJan 02Option Exercise59.825,500329,0109,460Jan 06 11:19 AM
SHERWIN STEPHEN ADirectorJan 02Sale279.285,5001,536,0593,960Jan 06 11:19 AM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale285.90439125,51013,667Dec 05 02:53 PM
SCHENK LYNNDirectorDec 02Sale291.711,000291,7104,100Dec 02 03:28 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Option Exercise49.954,000199,80012,710Nov 25 02:11 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Sale288.004,0001,152,0008,710Nov 25 02:11 PM
SCHENK LYNNDirectorNov 01Sale245.001,000245,0005,100Nov 05 12:18 PM
SCANGOS GEORGE AChief Executive OfficerNov 01Sale245.572,239549,83139,044Nov 05 12:13 PM